Evolus (NASDAQ:EOLS) had its target price trimmed by HC Wainwright from $37.00 to $34.00 in a report published on Thursday morning, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the stock.
EOLS has been the subject of several other research reports. Svb Leerink initiated coverage on Evolus in a report on Tuesday, November 26th. They issued an outperform rating and a $25.00 price target for the company. BidaskClub raised Evolus from a strong sell rating to a sell rating in a report on Thursday. ValuEngine raised Evolus from a buy rating to a strong-buy rating in a report on Thursday, January 23rd. Mizuho assumed coverage on Evolus in a research note on Wednesday, February 5th. They issued a buy rating and a $20.00 price objective on the stock. Finally, Leerink Swann assumed coverage on Evolus in a research note on Tuesday, November 26th. They issued an outperform rating and a $25.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Evolus presently has a consensus rating of Buy and an average target price of $25.18.
Evolus stock opened at $10.23 on Thursday. The business has a 50 day moving average price of $10.44 and a two-hundred day moving average price of $13.76. The company has a quick ratio of 3.28, a current ratio of 3.66 and a debt-to-equity ratio of 4.53. The stock has a market cap of $341.94 million, a price-to-earnings ratio of -3.19 and a beta of 4.30. Evolus has a 12 month low of $9.20 and a 12 month high of $29.50.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. boosted its position in Evolus by 2,224.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock valued at $34,000 after buying an additional 2,224 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Evolus in the 4th quarter valued at $30,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Evolus in the 1st quarter valued at $83,000. Royal Bank of Canada lifted its stake in shares of Evolus by 429.1% in the 2nd quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock valued at $64,000 after purchasing an additional 3,540 shares during the period. Finally, FMR LLC lifted its stake in shares of Evolus by 1,328.6% in the 4th quarter. FMR LLC now owns 5,000 shares of the company’s stock valued at $61,000 after purchasing an additional 4,650 shares during the period. Hedge funds and other institutional investors own 41.87% of the company’s stock.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.